PubMed HealthSearch

PubMed · 1951400

Therapeutic algorithm for chronic obstructive pulmonary disease.

Abstract

It would be foolhardy to offer an inflexible step-care protocol for the management of chronic obstructive pulmonary disease, given its heterogeneity and our uncertainty about its pathogenesis. Instead, the following outline might be regarded as a statement of principles to guide individual treatment plans. Smoking cessation is an essential, if difficult, first step, which is necessary to slow the accelerated rate of decline in pulmonary function that is characteristic of this disease. There is a compelling rationale for the use of influenza and pneumococcal vaccination, although proof of efficacy is lacking. If airways obstruction is present, inhaled quaternary anticholinergic bronchodilators seem to offer the greatest benefit with fewest side effects, making them the obvious first choice in bronchodilator therapy. In some patients, the addition of beta-agonists, theophylline, or both may augment bronchodilation. If significant airways obstruction persists despite the foregoing, an oral steroid trial is required. Some carefully selected patients whose exercise capacity has been limited despite optimal medical therapy may respond to a supervised exercise rehabilitation program. If hypoxemia is present, supplemental oxygen improves survival. Additional therapeutic modalities, ranging from preventive antioxidant administration to lung transplantation, remain investigational.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K R Chapman. 1991-10-21. Therapeutic algorithm for chronic obstructive pulmonary disease.. https://doi.org/10.1016/0002-9343(91)90257-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Synthesis of theophylline-polyrotaxane conjugates and their drug release via supramolecular dissociation.

Theophylline-polyrotaxane conjugates were synthesized by coupling theophylline with alpha-cyclodextrins (alpha-CDs) in the polyrotaxane. The polyrotaxane is a molecular assembly in which many alpha-CDs are threaded onto a poly(ethylene glycol) (PEG) chain capped with L-phenylalanine (L-Phe). Theophylline-7-acetic acid was activated by coupling with 4-nitrophenol, and then ethylenediamine was allowed to react with the active ester in order to obtain N-aminoethyl-theophylline-7-acetoamide. This derivative was coupled with a 4-nitrophenyl chloroformate-activated polyrotaxane to obtain the theophylline-polyrotaxane conjugates. The conjugates formed a specific association under physiological conditions, depending upon interactions between the theophylline molecules and/or the terminal l-Phe moiety in the conjugates. In vitro degradation of the conjugates revealed that theophylline-immobilized alpha-CDs were completely released by hydrolysis of the terminal peptide linkage in the polyrotaxane. This result indicates that the association of the conjugates does not induce the steric hindrance but rather enhances the accessibility of enzymes to the terminal peptide linkages. It is suggested that our designed drug-polyrotaxane conjugates can release the drugs via the dissociation of the supramolecular structure without steric hindrance of enzymatic accessibility to the terminal peptide linkages.

Bronchodilator Agents

Efficiency of continuous positive airway pressure versus theophylline therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality.

Sleep apnea is the most common sleep-related breathing disorder characterized by repetitive episodes of hypoxemia. Therapies include behavioral, surgical, orthodontic, pneumological, and pharmacological interventions. The aim of the present study was to compare the efficiency of pneumological therapy by nasal continuous positive airway pressure (CPAP) versus a pharmacological approach with theophylline (Respicur retard(R) 400 mg) on respiratory variables as well as objective and subjective sleep and awakening quality in patients with moderate sleep apnea measured by polysomnography and psychometry. Under CPAP therapy all respiratory variables improved and normalized, while under theophylline only the apnea-hypopnea index and the desaturation index improved but still did not return to normal values. Regarding sleep initiation and maintenance, CPAP therapy prolonged sleep latency and reduced movement time, while patients treated with theophylline showed reduced total sleep period, total sleep time and sleep efficiency. Sleep architecture demonstrated an increase in deep sleep and REM stages under CPAP therapy, and remained unchanged under theophylline. Concerning subjective sleep and awakening quality, both treatments improved well-being in the morning. Regarding objective awakening quality, reaction time performance was improved in both groups. In conclusion, CPAP treatment is more effective than theophylline regarding respiratory variables as well as the normalization of sleep maintenance and sleep architecture in sleep apnea patients.

Bronchodilator Agents